ADC Shows Survival Benefit in Mets Cervical Cancer
The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.
MDedge News
source https://www.medscape.com/s/viewarticle/998004?src=rss
MDedge News
source https://www.medscape.com/s/viewarticle/998004?src=rss
Comments
Post a Comment